EGb 761® (definition see editorial) Ginkgo extract is produced by a validated production process. Its pharmacologically active constituents, flavonol glycosides and terpene lactones, are kept within a narrow range of 22 to 27 % and 5 to 7 %, respectively, by standardisation. The concentration of ginkgolic acids is below 5 ppm. The constant production process also maintains the concentrations of other constituents such as proanthocyanidins, carboxylic acids and non-flavone glycosides at a fairly constant level. In this article, we will summarise the data on the pharmacokinetics of flavonol glycosides and terpene lactones.
References
-
1
Bhattaram V A, Graefe U, Kohlert C, Veit M, Derendorf H.
Pharmacokinetics and bioavailability of Herbal Medicinal Products.
Phytomedicine.
2002;
9(Suppl 3)
1-33
-
2
Biber A, Koch E.
Bioavailaility of ginkgolides and bilobalide from extracts of Ginkgo biloba using GC/MS.
Planta Med.
1999;
65
192-193
-
3 Chatterjee S S, Jaggy H. Divergent pharmacological properties of different extracts of Ginkgo biloba. Poster 1st Int. Congr Ethnopharmacol 1990: p. 61
-
4 DeFeudis F V. Ginkgo biloba extract (EGb 761®). From chemistry to the clinic. Ullstein Medical Wiesbaden; 1998
-
5
De Smet P AGM, Brouwers J RBJ.
Pharmacokinetic evaluation of herbal remedies. Basic introduction, applicability, current status and regulatory needs.
Clin Pharmacokinet.
1997;
32
427-436
-
6
Drieu K. et al .
Animal distribution and preliminary human kinetic studies of the flavonoid fraction of a standardized Ginkgo extract (EGb 761®).
Stud Org Chem.
1986;
23
351-359
-
7
Fourtillan J B, Brisson A M, Girault J, Ingrand I, Decourt J P, Drieu K, Jouenne P, Biber A.
Propriétés pharmacocinetiques du bilobalide et des ginkgolides A et B chez le sujet sain près administrations intraveineuses et orales d’extrait de ginkgo biloba (EGb 761®).
Therapie.
1995;
50
137-144
-
8
Graefe E U, Derendorf H, Veit M.
Pharmacokinetics and bioavailability of the flavonol quercetin in humans.
Int J Clin Pharmacol Ther.
1999;
37
219-233
-
9
Graefe E U. et al .
Pharmacokinetics and bioavailability of quercetin glycosides in humans.
J Clin Pharmacol.
2001;
41
492-499
-
10
Hollman P CH, Katan M B.
Absorption, metabolism and health effects of dietary flavonoids in man.
Biomed Pharmacother.
1997;
51
305-310
-
11 Internal Report (1989) AD 846H.
-
12 Internal Report (1993) AD 969H.
-
13 Internal Report (1995) WS 0695/1.
-
14
Jaggy H.
Die Inhaltsstoffe des Ginkgo-biloba-Extraktes EGb 761®.
Hämostaseologie.
1993;
13
7-10
-
15
Masri M S, Booth A M, DeEds F.
The metabolism and acid degradation of quercetin.
Arch Biochem Biophys.
1959;
85
284-286
-
16
Mauri P, Simonetti P, Gardana C, Minoggio M, Morazzoni P, Bombardelli E, Pietta P.
Liquid chromatography/atmospheric pressure chemical ionization mass spectrometry of terpene lactones in plasma of volunteers dosed with Ginkgo biloba L. extracts.
Rapid Comm Mass Spect.
2001;
15
929-934
-
17 Moreau J P. et al .Absorption, distribution and excretion of tagged Ginkgo biloba leaf extract in the rat. Rökan Ginkgo biloba. Recent results in pharmacology and clinic. Fünfgeld (ed) Springer 1988: pp 37-45
-
18
Nieder M.
Pharmakokinetik der Ginkgo-Flavonole im Plasma.
MMW.
1991;
133
S61
-
19
Oliveira E J, Watson D G.
In vitro glucuronidation of kaempferol and quercetin by human UGT-1A9 microsomes.
FEBS Lett.
2000;
471
1-6
-
20
Pietta P G. et al .
Identification of flavonoid metabolites after oral administration to rats of a Ginkgo biloba extract.
J Chromatogr.
1995;
673
75-80
-
21
Pietta P G. et al .
Identification of Ginkgo biloba flavonol metabolites after oral administration to humans.
J Chromatogr.
1997;
693
249-255
-
22
Sugiyama C. et al .
Improvement of oral absorption of Ginkgo biloba extract by use of excipients.
Yakuzaigaku.
1998;
58
52-58
-
23
Watanabe C M, Wolffram S, Ader P, Rimbach G, Packer L, Maguire J J, Schultz P G, Gohil K.
The in vivo neuromodulatory effects of the herbal medicine ginkgo biloba.
PNAS.
2001;
98
6577-6580
-
24
Watson D G, Oliveira E J.
Solid-phase extraction and GC/MS determination of kaempferol and quercetin in human urine after consumption of Ginkgo biloba tablets.
J Chromatogr.
1999;
723
203-210
-
25
Watson D G, Pitt A R.
Analysis of flavonoids in tablets and urine by GC/MS and LC/MS.
Rapid Comm Mass Spec.
1998;
12
153-156
Dr. Anton Biber
Abt. Forschung und Entwicklung
Dr. Willmar Schwabe GmbH & Co. KG
76227 Karlsruhe
Germany
Telefon: +49 (721) 40 05-335
Fax: +49 (721) 40 05-557
eMail: anton.biber@schwabe.de
